These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1791768)

  • 61. Endometrial effects of a continuous percutaneous oestrogen/low dose oral progestogen regimen for climacteric complaints.
    Holst J; Cajander S; von Schoultz B
    Maturitas; 1987 Apr; 9(1):63-7. PubMed ID: 3110563
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study.
    Kok AL; Burger CW; van de Weijer PH; Voetberg GA; Peters-Muller ER; Kenemans P
    Maturitas; 1999 Jan; 31(2):143-9. PubMed ID: 10227008
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
    Mijatovic V; Kenemans P; Netelenbos C; Jakobs C; Popp-Snijders C; Peters-Muller ER; van der Mooren MJ
    Fertil Steril; 1998 May; 69(5):876-82. PubMed ID: 9591496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime.
    Vashisht A; Wadsworth F; Carey A; Carey B; Studd J
    BJOG; 2005 Oct; 112(10):1402-6. PubMed ID: 16167944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium.
    Pansini F; De Paoli D; Albertazzi P; Bonaccorsi G; Campobasso C; Zanotti L; Pisati R; Giulini NA
    Eur J Obstet Gynecol Reprod Biol; 1996 Sep; 68(1-2):137-41. PubMed ID: 8886696
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vaginal administration of low-dose oestradiol--effects on the endometrium and vaginal cytology.
    Mattsson LA; Cullberg G; Eriksson O; Knutsson F
    Maturitas; 1989 Sep; 11(3):217-22. PubMed ID: 2593865
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A burning mouth associated with the use of hormone replacement therapy.
    Palin SL; Kumar S; Barnett AH; Sturdee DW
    J Br Menopause Soc; 2005 Mar; 11(1):38. PubMed ID: 15814062
    [No Abstract]   [Full Text] [Related]  

  • 70. [Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy].
    Scheen AJ; Gaspard U
    Rev Med Liege; 2011 Apr; 66(4):209-14. PubMed ID: 21638840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trough oestradiol levels associated with cognitive impairment in post-menopausal women after 10 years of oestradiol implants.
    File SE; Heard JE; Rymer J
    Psychopharmacology (Berl); 2002 Apr; 161(1):107-12. PubMed ID: 11967638
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women.
    Piróg M; Jach R; Kacalska-Janssen O
    Acta Obstet Gynecol Scand; 2017 Dec; 96(12):1438-1445. PubMed ID: 28981954
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept.
    Fatemi HM; Bourgain C; Donoso P; Blockeel C; Papanikolaou EG; Popovic-Todorovic B; Devroey P
    Hum Reprod; 2007 May; 22(5):1260-3. PubMed ID: 17227809
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Maturitas; 2004 Nov; 49(3):253-63. PubMed ID: 15488354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study.
    Al-Azzawi F; Wahab M; Thompson J; Whitehead M; Thompson W
    Hum Reprod; 1999 Mar; 14(3):636-41. PubMed ID: 10221688
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome.
    Watson NR; Studd JW; Savvas M; Baber RJ
    Gynecol Endocrinol; 1990 Jun; 4(2):99-107. PubMed ID: 2118709
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of two equine oestrogen-dydrogesterone regimens in the climacteric.
    Caudron J; Hendrickx B
    Maturitas; 1988 Jul; 10(2):133-41. PubMed ID: 3047526
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dydrogesterone after 60 years: a glance at the safety profile.
    Ott J; Egarter C; Aguilera A
    Gynecol Endocrinol; 2022 Apr; 38(4):279-287. PubMed ID: 34927507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.